1d321717 7ef9 44e1 a535 7a7c6aba1c79


Cytognomix creates and and sells novel genome bioinformatic products for diagnostic applications. We find and validate mutations that others cannot.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location London, ON, Canada
  • Currency USD
  • Founded December 2009
  • Employees 4
  • Website

Company Summary

Cytognomix is a London, Ontario based biotechnology company developing software-based solutions and reagents for clinical genomics. The company has a significant intellectual property portfolio, which emphasizes products for clinical diagnostic applications. Current products include mutation interpretation software, DNA probe reagents and companion software to detect chromosome abnormalities at the molecular level.


  • Default avatar
    Joan Knoll
    Chief Scientific Officer

    Dr. Knoll is direct Director of the Laboratory of Genomic Disorders, Schulich School of Medicine, at the University of Western Ontario is Professor in Pathology and is certified by the American Board of Medical Genetics in Cytogenetics and Molecular Genetics. She is also Medical Leader of Molecular Pathology at London Health Sciences Center, London Ontario. She has directed clinical cytogenetics laboratories at several academic research institut

  • Default avatar
    Peter Rogan

    Dr Rogan is an internationally recognized researcher in human genomics and bioinformatics who has authored more than 100 scientific publications and holds several related patents. As an inventor of SC technology, Dr. Rogan is president of Cytognomix. Dr. Rogan is a serial entrepreneur, having founded Phylogenetix Laboratories, a US company where preliminary development of SC technology occurred under a NIH SBIR grant. Dr. Rogan is currently Prof


  • Default avatar
    Harrison Pensa LLC
    Default avatar
    Price Waterhouse Coopers LLC

Previous Investors

  • Default avatar
    Ontario Genomics Institute